Novartis AG (BUE:NVS) Cyclically Adjusted Book per Share: ARS11,762.75 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:NVS Novartis AG BUE:NVS
64 GF Score
Price ARS59,250.00
GF Value ARS50,207.09
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novartis AG Cyclically Adjusted Book per Share?

Novartis AG BUE:NVS +1.28% 64 Cyclically Adjusted Book per Share is ARS11,762.75 as of Mar. 2026. GuruFocus rates BUE:NVS with a GF Score™ of 64/100 and a GF Value™ of ARS50,207.09 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novartis AG's adjusted book value per share for the three months ended in Mar. 2026 was ARS56,442.996. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS11,762.75 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novartis AG's average Cyclically Adjusted Book Growth Rate was -5.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -0.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novartis AG was 4.60% per year. The lowest was -3.20% per year. And the median was 2.70% per year.

As of today (2026-07-16), Novartis AG's current stock price is ARS59250.00. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ARS11,762.75. Novartis AG's Cyclically Adjusted PB Ratio of today is 5.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 5.11. The lowest was 2.23. And the median was 2.84.


Novartis AG  (BUE:NVS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=59250.00/11762.75
=5.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 5.11. The lowest was 2.23. And the median was 2.84.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novartis AG Cyclically Adjusted Book per Share Related Terms


Novartis AG Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted Book per Share Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,554.74 2,701.69 7,939.74 8,881.98 12,363.18

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,045.89 10,137.31 12,780.72 12,363.18 11,762.75

BUE:NVS vs LLY, JNJ, ABBV: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.


BUE:NVS
64GF Score
Novartis AG BUE:NVS
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=56442.996/108.0600*108.0600
=56,442.996

Current CPI (Mar. 2026) = 108.0600.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201606 850.760 100.088 918.525
201609 941.711 99.604 1,021.658
201612 999.363 99.380 1,086.654
201703 880.938 100.040 951.562
201706 984.101 100.285 1,060.395
201709 1,093.563 100.254 1,178.716
201712 1,222.235 100.213 1,317.940
201803 1,229.238 100.836 1,317.307
201806 1,650.242 101.435 1,758.022
201809 2,483.152 101.246 2,650.285
201812 2,565.054 100.906 2,746.910
201903 1,589.598 101.571 1,691.155
201906 2,005.140 102.044 2,123.355
201909 2,594.239 101.396 2,764.747
201912 2,927.920 101.063 3,130.626
202003 2,760.994 101.048 2,952.602
202006 3,218.874 100.743 3,452.659
202009 3,556.731 100.585 3,821.066
202012 4,081.797 100.241 4,400.199
202103 4,054.284 100.800 4,346.298
202106 4,577.554 101.352 4,880.515
202109 4,962.754 101.533 5,281.808
202112 6,114.239 101.776 6,491.785
202203 5,972.814 103.205 6,253.789
202206 6,937.701 104.783 7,154.685
202209 7,857.684 104.835 8,099.422
202212 9,387.280 104.666 9,691.662
202303 9,808.541 106.245 9,976.130
202306 12,032.584 106.576 12,200.187
202309 12,995.137 106.570 13,176.889
202312 16,483.862 106.461 16,731.411
202403 32,764.252 107.355 32,979.445
202406 36,918.177 107.991 36,941.800
202409 41,187.840 107.468 41,414.767
202412 45,047.527 107.128 45,439.392
202503 41,753.414 107.722 41,884.268
202506 51,497.671 108.075 51,490.476
202509 62,748.531 107.710 62,952.430
202512 70,180.140 107.200 70,743.152
202603 56,442.996 108.060 56,442.996

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ARS11,762.75 mean?
Novartis AG (BUE:NVS) has a Cyclically Adjusted Book per Share of ARS11,762.75 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novartis AG and its competitors.
Is Novartis AG's Cyclically Adjusted Book per Share too high?
Novartis AG's current Cyclically Adjusted Book per Share is ARS11,762.75. Overall, Novartis AG has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Cyclically Adjusted Book per Share compare to LLY and JNJ?
Novartis AG's Cyclically Adjusted Book per Share of ARS11,762.75 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novartis AG and its competitors. Novartis AG's current Cyclically Adjusted Book per Share is ARS11,762.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (BUE:NVS) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS50,207.09, compared to a current price of ARS59,250.00 — trading 18% above its estimated fair value. The current Cyclically Adjusted Book per Share is ARS11,762.75. Novartis AG's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novartis AG (BUE:NVS), the current Cyclically Adjusted Book per Share is ARS11,762.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (BUE:NVS) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of ARS59,250.00 is trading 18% above its estimated GF Value™ of ARS50,207.09. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for BUE:NVS:

  • Cyclically Adjusted Book per Share: ARS11,762.75
  • GF Value™: ARS50,207.09 vs. price of ARS59,250.00 (18% above fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the BUE:NVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
64GF Score

Get the complete analysis for BUE:NVS

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS59,250.00
Price
ARS50,207.09
GF Value